Korean J Urol.  2011 Mar;52(3):178-183.

Effectiveness and Safety of Photoselective Vaporization of the Prostate with the 120 W HPS Greenlight Laser in Benign Prostatic Hyperplasia Patients Taking Oral Anticoagulants

• Sohn JH
• Choi YS
• Kim SJ
• Cho HJ
• Hong SH
• Lee JY
• Hwang TK
• Kim SW

Abstract

PURPOSE
To examine the effectiveness and safety of photoselective vaporization of the prostate (PVP) with the 120 W high-performance system (HPS) Greenlight laser procedure in benign prostatic hyperplasia (BPH) patients taking oral anticoagulant medications.
MATERIALS AND METHODS
This study was conducted on BPH patients taking oral anticoagulant medications form March 2009 to December 2010. Group I consisted of patients who stopped oral anticoagulant medications before surgery (n=30), and group II consisted of patients who continued oral anticoagulant medications before surgery (n=30). PVP applying the 120 W HPS Greenlight laser was done, and followed up for 12 weeks. Follow-up variables were International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR), and hemoglobin level change.
RESULTS
At 12 weeks after surgery, we confirmed the improvement in the IPSS score of Group I compared with preoperative scores. The quality of life (QoL) score, Qmax and PVR were also improved. respectively, both of which were significantly improved. In Group II, similarly, the total IPSS score, the voiding symptom score, and the storage symptom score were improved in comparison with the preoperative scores. The QoL score, Qmax and the PVR were improved in comparison with the preoperative scores. During the 12-week follow-up period, no major postsurgical complications requiring transfusion, rehospitalization, etc. were observed.
CONCLUSIONS
The 120 W HPS Greenlight laser PVP procedure can be performed effectively and safely in BPH patients, even those who cannot stop oral anticoagulant medications despite requiring surgery.

Keyword

Anticoagulants; Laser therapy; Prostatic hyperplasia

MeSH Terms

Anticoagulants
Follow-Up Studies
Hemoglobins
Humans
Laser Therapy
Prostate
Prostatic Hyperplasia
Quality of Life
Volatilization
Anticoagulants
Hemoglobins

Figure

• 

  FIG. 1 The change in perioperative IPSS parameters of Group I and Group II. IPSS: International Prostate Symptom Score, QoL: quality of life.

Reference

1. Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol. 2008. 180:241–245.

2. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006. 50:969–979.

3. Fitzpatrick JM, Mebust KW. Walsh CW, Retik AB, Vaughan ED, Wein AJ, editors. Minimally invasive and endoscopic management of benign prostatic hyperplasia. Campbell's urology. 2004. 8th ed. Philadelphia: WB Saunders;1402.

4. Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. J Urol. 2004. 172:616–619.

5. Gürdal M, Tekin A, Yücebaş EE, Sengör F. Nd:YAG laser ablation plus transurethral resection for large prostates in high-risk patients. Urology. 2003. 62:914–917.

6. Shingleton WB, Farabaugh P, May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology. 2002. 60:305–308.

7. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatectomy: mortality and morbidity. Prostate. 1996. 28:195–200.

8. Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, et al. Factors influencing morbidity in patients under-going transurethral resection of the prostate. Urology. 1999. 53:98–105.

9. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992. 147:1566–1573.

10. Hedlund PO. Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test. Scand J Urol Nephrol. 1975. 27 Suppl. 1–100.

11. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997. 336:1506–1511.

12. Wong C, Araki M, Tonkin JB. High-power potassium-titanyl-phosphate or lithium triboride laser photoselective vaporization prostatectomy for benign prostatic hyperplasia: a systematic approach. J Endourol. 2007. 21:1141–1144.

13. Chakravarti A, MacDermott S. Transurethral resection of the prostate in the anticoagulated patient. Br J Urol. 1998. 81:520–522.

14. Tscholl R, Straub W, Zingg E. Electroresection of the prostate in patients treated with heparin. J Urol. 1980. 124:221–222.

15. Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol. 2002. 168:610–613.

16. Bell CR, Murdock PJ, Pasi KJ, Morgan RJ. Thrombotic risk factors associated with transurethral prostatectomy. BJU Int. 1999. 83:984–989.

17. Te AE. The development of laser prostatectomy. BJU Int. 2004. 93:262–265.

18. Carter A, Sells H, Speakman M, Ewings P, MacDonagh R, O'Boyle P. A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. BJU Int. 1999. 83:254–259.

19. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol. 2000. 163:1730–1733.

20. Alivizatos G, Skolarikos A. Greenlight laser in benign prostatic hyperplasia: turning green into gold. Curr Opin Urol. 2008. 18:46–49.

21. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert H, Müller A, et al. Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol. 2005. 47:798–804.

22. Sarica K, Alkan E, Lüleci H, Taşci AI. Photoselective vaporization of the enlarged prostate with KTP laser: long-term results in 240 patients. J Endourol. 2005. 19:1199–1202.

23. Ko DW, Jeong BC, Son H. Initial experience with a new 120 W Greenlight™ high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea. Korean J Urol. 2009. 50:1089–1094.

24. Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005. 48:965–971.

25. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol. 2006. 20:580–585.

26. Kim HS, Cho MC, Ku JH, Kim SW, Paick JS. The efficacy and safety of photoselective vaporization of the prostate with a potassium-titanyl-phosphate laser for symptomatic benign prostatic hyperplasia according to prostate size: 2-year surgical outcomes. Korean J Urol. 2010. 51:330–336.

27. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol. 2005. 174:1344–1348.

28. Pfitzenmaier J, Gilfrich C, Pritsch M, Herrmann D, Buse S, Haferkamp A, et al. Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL. BJU Int. 2008. 102:322–327.

29. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology. 2004. 64:1155–1159.

30. Ruszat R, Wyler S, Seifert HH, Reich O, Forster T, Sulser T, et al. Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol. 2006. 50:1040–1049.